Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 in NSCLC with meningeal metastasis (Phase Ib/II)
ChiCTR2600117576Phase 2Completed
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of BioTTT001 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: DLT, MTD and/or RP2D; incidence and severity of adverse events. Started Jan 2026; status: completed.
02
Drugs
BioTTT001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117576.